Neglected Tropical Diseases (NTDs)

Neglected Tropical Diseases (NTDs)

Genna Print / WHO

Neglected tropical diseases affect poor and marginalized populations, with children especially neglected. For sleeping sickness (human African trypanosomiasis), treatments can either be too toxic for children (such as for the Trypanosoma brucei rhodesiense parasite) or problematic to administer (intravenous administration). Although there is currently an effective oral treatment for adults, the dosage of this drug (fexinidazole) does not include children younger than six years of age or weighing less than 20 kg or those with advanced disease. As there is only one oral drug (miltefosine) for the life-threatening kalaazar (black fever or visceral leishmaniasis), combination therapies inevitably include one or more injectable drugs, which are painful or cumbersome to administer to children. For snail fever (schistosomiasis), paediatric formulations became available, but not widely accessible. For current treatment of river blindness (onchocerciasis) through mass drug administration, children weighing less than 15 kg are excluded because there is no approved dosing for this category or suitable paediatric formulation. For Chagas disease, a hidden, silent disease, even though two effective paediatric treatments are available, uptake is very low, necessitating greater political will and commitment to change the situation.

Portfolio products

10 products · PADO-NTDs
● Access list: 0    ● Priority list: 7    ● Watch list: 3
0 Access
7 Priority
3 Watch

PADO-NTDs priority list 7
Schistosomiasis
L-praziquantel
150 mg ODT
L-praziquantel
300 mg scored ODT*
Scabies & Onchocerciasis
Ivermectin
1 mg or 1.5 mg ODT**
Moxidectin
Oral dosage form***
Human African Trypanosomiasis
Acoziborole
320 mg paediatric oral dosage form**
Visceral Leishmaniasis
Miltefosine
20 mg scored dispersible tablets
Amphotericin B
Oral solid dosage form**
PADO-NTDs watch list 3
Scabies & Onchocerciasis
Emodepside
Oxfendazole
Visceral Leishmaniasis
LXE408
Updates since PADO exercise
2
Regulatory & Prequalification
L-praziquantel (arpraziquantel)
150 mg DT approved by EMA and added to the WHO prequalification list
Acoziborole
320 mg tablet approved by EMA (DNDi details →)
* Pending confirmation of chemistry, manufacturing and controls feasibility
** To be confirmed
*** Details of dosage form and strength to cover the full age and weight spectrum for children and adolescents to be determined based on ongoing studies

PADO report

Paediatric drug optimization for neglected tropical diseases: meeting report, September 2023
WHO convened and facilitated a paediatric exercise for neglected tropical diseases to ensure that more targeted research and development efforts can address...